{
  "report_rows": [
    {
      "kpi": "Adjusted EBITDA (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$655M vs. cons $636.2M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "WWE Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$635M vs. cons $619.7M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Partnerships & Marketing Revenue (Q2 2026)",
      "prediction": "BEAT",
      "answer": "pred ~$205M vs. cons $198.7M",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY 2026 Adj. EBITDA (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide reaffirm $2,240M-$2,290M vs. cons $2,273M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "FY 2026 Revenue (FY 2026)",
      "prediction": "UNCHANGED",
      "answer": "guide reaffirm $5,675B-$5,775B vs. cons $5,766M",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Capital Returns / Buyback (qualitative)",
      "prediction": "BETTER",
      "answer": "guide continuation of $200M 10b5-1 + color on remaining $1B+ authorization vs. no consensus",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -1.0,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": -1.5,
  "day5_path": "STABILIZE",
  "day5_rationale": "STABILIZE \u2014 short covering limits further downside; no FY raise to drive estimate upgrades; EBITDA revision trend stops bleeding but does not reverse",
  "day5_confidence": "MEDIUM"
}